Crohn’s disease symptoms usually build slowly, which is why the condition is often blamed on a sensitive stomach or on stress for months before anyone orders the right test. Crohn’s is a lifelong inflammatory condition of the digestive tract that can affect any segment from mouth to anus, most often the last part of the small intestine. It flares and quiets down, and the inflammation behind it does not always match how a person feels on a given day. That mismatch is why lab work has become central to modern care. In this article you will learn which symptoms point toward Crohn’s, what drives the inflammation, how the diagnosis is confirmed, which blood and stool markers track disease activity between appointments, and what current treatments offer.
What Crohn’s disease is
Crohn’s disease belongs to a family of conditions called inflammatory bowel disease. The immune system attacks the lining of the digestive tract, and in Crohn’s that attack goes deep: inflammation can pass through the full thickness of the bowel wall. Doctors call this transmural inflammation, and it explains complications specific to Crohn’s, such as narrowed segments and abnormal tunnels between organs.
The second defining feature is that the damage is patchy: healthy tissue can sit directly next to inflamed tissue, producing what clinicians call skip lesions. A 2024 clinical review in a major general medical journal described the end of the small intestine and the start of the colon as the most commonly involved area, with segmental, discontinuous inflammation as the typical pattern.
Where the inflammation sits
Cleveland Clinic describes five patterns: ileocolitis, involving the end of the small intestine and the colon, which is the most common form; Crohn’s colitis, limited to the large intestine; ileitis, confined to the final small intestine segment; gastroduodenal disease, affecting the stomach and the start of the small intestine; and jejunoileitis, producing patches in the upper small intestine. The pattern shapes both the symptoms and the choice of monitoring test.
How it differs from ulcerative colitis
The other main form of inflammatory bowel disease affects only the colon, starts at the rectum and moves upward without gaps, and stays in the inner lining. Crohn’s can appear anywhere, skips around, and burrows through the wall. Because the two share fatigue, urgency and bloody stools, many readers also review the symptoms and treatment options of ulcerative colitis.
Crohn’s disease symptoms you can notice
Symptoms depend on where the inflammation sits and how deep it runs. Two people with the same diagnosis can describe very different experiences, and severity shifts over months rather than days.
Digestive symptoms
- Diarrhea that persists for weeks, sometimes waking you at night
- Cramping and pain, classically in the lower right abdomen
- Blood or mucus in the stool
- Urgency, or the feeling that the bowel has not fully emptied
- Pain, swelling or drainage around the anus
- Mouth sores that keep coming back
Whole-body symptoms
Because inflammation and poor absorption run in the background, many of the most disruptive complaints have nothing to do with the bathroom. Mayo Clinic lists fatigue, low-grade fever, reduced appetite and unintended weight loss among the core features. Children may grow slowly or start puberty late, sometimes the first clue a family notices.
Symptoms outside the gut
Crohn’s can involve joints, skin and eyes. Joint pain and swelling, tender red bumps on the shins, painful leg ulcers, and red or painful eyes all occur more often than in the general population. Inflammation of the bile ducts, kidney stones and thinning bones after long steroid exposure are also recognized.
When to see a doctor
Book an appointment if diarrhea lasts more than two weeks, if you see blood in the stool more than once, if abdominal pain wakes you at night, or if you lose weight without trying. Seek urgent care for severe unrelenting abdominal pain with vomiting and no passage of gas or stool, which can signal a blockage. Delays matter: the longer inflammation runs unchecked, the more likely it leaves permanent narrowing behind.
What causes Crohn’s disease
No single cause has been identified. Several factors have to line up. Certain inherited variants make the immune system more likely to overreact to the normal bacteria living in the gut. Mayo Clinic notes that up to one in five people with Crohn’s has a close relative with inflammatory bowel disease, which also means most patients have no family history. Diagnosis most often happens before age 30.
Environment supplies the trigger. Smoking is the most important modifiable risk factor and is linked to more aggressive disease and more surgery. Frequent use of nonsteroidal anti-inflammatory drugs can irritate the bowel lining and provoke flares. Shifts in the gut microbial community, early antibiotic exposure and diets heavy in ultra-processed food have all been studied, though none causes Crohn’s on its own. Stress and food do not create the disease, but they influence how loudly it speaks.
How Crohn’s disease is diagnosed
The NIDDK, part of the National Institutes of Health, states plainly that no single test diagnoses Crohn’s disease. The diagnosis is assembled from history, physical examination, laboratory results, direct visualization of the bowel and tissue samples.
The laboratory work that starts the process
The first round of testing does two things: it looks for evidence of inflammation, and it rules out infection. Doctors most often order a fecal calprotectin stool test, which measures a protein released by white blood cells inside the intestine and is the most direct non-invasive signal of gut inflammation. Blood work usually includes a C-reactive protein measurement and a complete blood count. Stool cultures exclude infection, and doctors sometimes order a fecal occult blood test when bleeding is suspected but not visible.
Before settling on Crohn’s, clinicians also rule out celiac disease, irritable bowel syndrome and infectious colitis, which can look similar early on.
Endoscopy, biopsy and imaging
Ileocolonoscopy with biopsies remains the reference standard: it lets the gastroenterologist see ulcers directly and take tissue that confirms the microscopic pattern. Because Crohn’s can involve small bowel beyond the reach of a scope, imaging completes the map. MRI enterography and intestinal ultrasound show how deep the inflammation runs and reveal abscesses or narrowed segments.
The lab markers that track Crohn’s disease between visits
This is where care has changed most. Symptoms alone are an unreliable guide: some people feel fine while ulcers persist, others have severe discomfort with a calm bowel. The American Gastroenterological Association published a clinical practice guideline on biomarkers in Crohn’s disease that recommends combining symptom review with stool and blood markers rather than relying on how a patient feels. In someone whose symptoms have settled, a fecal calprotectin below roughly 150 micrograms per gram plus a normal C-reactive protein makes active inflammation unlikely and can spare a colonoscopy. Raised markers in that situation should be confirmed by endoscopy before treatment changes.
| Lab marker | What it reflects in Crohn’s disease | Why a change matters |
|---|---|---|
| Fecal calprotectin | White blood cells migrating into the bowel lining | The closest non-invasive stand-in for what a scope would show; rising values often precede a flare |
| C-reactive protein | General inflammation anywhere in the body | Useful and cheap, but some people never mount a CRP response even with active disease |
| Hemoglobin and complete blood count | Blood loss, chronic inflammation, immune activity | Falling hemoglobin points to bleeding or poor iron use; a rising platelet count can accompany a flare |
| Ferritin and transferrin saturation | Iron stores and iron available for red cell production | Ferritin rises with inflammation, so it is read alongside saturation rather than alone |
| Albumin | Protein status and ongoing inflammation | A drifting albumin can signal protein loss through an inflamed bowel or poor nutrition |
| Vitamin B12 | Absorption in the last part of the small intestine | Frequently low after ileal disease or ileal surgery, and a common cause of stubborn fatigue |
| Vitamin D | Fat-soluble vitamin absorption and bone health | Often low, and relevant to bone density after repeated steroid courses |
| Drug trough level and antibodies | How much medication is circulating and whether the body is neutralizing it | Explains why a treatment that once worked has stopped working |
Anemia and nutrition, the quiet part of the disease
Chronic blood loss and impaired absorption together produce iron deficiency anemia in Crohn’s more often than in most chronic conditions. A 2025 clinical review listed inflammatory bowel disease among the settings where iron deficiency is most common, and warned that ferritin alone can mislead when inflammation is present. Clinicians therefore check the ferritin level together with a serum iron measurement and transferrin saturation. They also track the serum albumin level, and after ileal disease or surgery many people need a vitamin B12 test. Because fat absorption suffers when the small intestine is inflamed, clinicians commonly measure vitamin D levels as well.
Treatment options for Crohn’s disease
There is no cure, but the goal has moved well beyond feeling better. Modern care aims at endoscopic healing, meaning ulcers that have actually closed, because that is what protects the bowel from long-term damage.
Corticosteroids and older medications
Corticosteroids, including budesonide for disease limited to the ileum, calm a flare quickly but are not meant for long-term use, given their effects on bone, blood sugar, mood and infection risk. Immunomodulators such as azathioprine, mercaptopurine and methotrexate work more slowly and often support a biologic rather than acting alone. Aminosalicylates play a smaller role in Crohn’s than in ulcerative colitis, and antibiotics are reserved for abscesses and perianal disease.
Biologics and small molecules
Advanced therapies target specific steps in the inflammatory cascade rather than suppressing immunity broadly.
- Anti-TNF antibodies, including infliximab, adalimumab and certolizumab pegol, block a central inflammatory messenger and remain a first-line choice, especially for perianal disease
- Vedolizumab blocks the traffic of inflammatory cells into the gut and acts mostly within the intestine
- Ustekinumab blocks two related messengers, interleukin-12 and interleukin-23
- Selective interleukin-23 blockers, a newer group including risankizumab, mirikizumab and guselkumab, target only the second messenger
- Upadacitinib, an oral Janus kinase inhibitor, works inside the cell and takes effect quickly
The choice depends on disease location, previous responses, other conditions, whether an infusion, injection or tablet suits your life, and safety factors weighed individually.
Therapeutic drug monitoring
Biologics are proteins, and the immune system can learn to neutralize them. Measuring the drug level in the blood just before the next dose, along with any antibodies formed against it, shows whether a treatment failure comes from too little drug, from antibodies, or from a mechanism that was never going to work for this patient. A 2024 review described this measurement as a routine part of managing biologics, and a 2025 pediatric position paper reached the same conclusion for children.
Surgery and nutrition
Many people with Crohn’s eventually need an operation, most often to remove a narrowed segment, drain an abscess or repair a fistula. Surgery is not a cure, since inflammation can return at the join, which is why stool marker testing is used afterward to catch recurrence early. Exclusive enteral nutrition is an established way to induce remission in children, and specific dietary patterns can ease symptoms, but no diet reliably heals the bowel by itself.
Living with Crohn’s disease
Most people with Crohn’s work, travel and raise families. The realistic picture is a long-term condition with quiet periods that can last years, punctuated by flares that need attention. Stopping smoking is the single most useful thing a patient can do for their own prognosis. Vaccinations matter more than average when immune-suppressing treatment is involved, and colon surveillance is advised after years of colonic disease.
Three habits help. Keep a record of symptoms and lab values so trends are visible rather than snapshots. Do not stop a maintenance medication because you feel well, since feeling well is not the same as healed. Report new perianal pain or drainage promptly, because early treatment of fistulas gives far better results.
Latest scientific advances
Research over the past three years has focused less on new drugs and more on knowing who needs which drug, and when.
Stool and blood markers can replace some colonoscopies
A 2023 American Gastroenterological Association guideline concluded that in people whose symptoms have settled, a low stool calprotectin with a normal C-reactive protein reliably indicates a calm bowel. What this means for you: if your markers are reassuring and you feel well, a scope can often wait. If markers and symptoms disagree, the scope is the tiebreaker.
Starting strong treatment early beat stepping up slowly
A 2024 randomized trial compared two strategies in people newly diagnosed with Crohn’s: beginning combined advanced therapy right away, or adding treatments only if simpler ones failed. Starting strong produced better sustained remission and less need for urgent intervention. A blood test used to sort patients into predicted high and low risk groups did not change which strategy worked best. What this means for you: an early conversation about advanced therapy is reasonable even if symptoms seem manageable.
A head-to-head comparison between two biologics
A 2024 trial compared risankizumab against ustekinumab in people whose disease had not responded adequately to anti-TNF treatment. Risankizumab was at least as effective for symptom remission and did better on the harder measure of visible healing inside the bowel. What this means for you: if a first advanced therapy has failed, direct comparative evidence now informs the next choice. This was an open-label study, meaning participants knew which drug they received, so the symptom findings carry slightly less weight than the endoscopy findings.
Tracking markers over time beats single readings
A 2025 study followed people treated with infliximab and tracked how stool calprotectin and C-reactive protein moved across many measurements rather than at one moment. The path each marker traced predicted who stayed well better than any isolated result. What this means for you: your last calprotectin value matters less than the direction it has been heading, so keeping results together makes the trend visible.
Measuring drug levels to explain treatment failure
A 2024 review and a 2025 pediatric position paper both concluded that measuring biologic drug levels and anti-drug antibodies distinguishes underdosing from immune neutralization. What this means for you: if a biologic seems to be losing effect, a blood test can show whether a dose adjustment will rescue it before switching drugs.
Wearable devices as an early warning signal
A 2025 study found that everyday data from wearable devices, such as heart rate patterns and heart rate variability, shifted in the weeks before an inflammatory bowel disease flare became obvious. What this means for you: promising but still early, and no substitute for lab testing. It hints at a future where a flare is caught before it disrupts your week.
Iron deficiency deserves more attention than it gets
A 2025 clinical review highlighted inflammatory bowel disease as a setting where iron deficiency is frequently missed, partly because inflammation pushes ferritin up and masks empty iron stores. What this means for you: persistent fatigue in Crohn’s deserves a full iron workup, not just a hemoglobin check, and intravenous iron is often preferred when the bowel is inflamed.
Glossary
| Term | Definition |
|---|---|
| Biologic | A medication made from living cells, usually an antibody, that blocks one specific step in the inflammatory process. Given by infusion or injection. |
| Fecal calprotectin | A protein released by white blood cells into the bowel. Measured in a stool sample, it indicates how much inflammation is present inside the intestine. |
| C-reactive protein (CRP) | A blood protein made by the liver that rises with inflammation anywhere in the body. It is fast and inexpensive but not specific to the gut. |
| Ferritin | The protein that stores iron. It reflects iron reserves, but it also rises during inflammation, so it is interpreted alongside other iron measurements. |
| Transmural inflammation | Inflammation that passes through the entire thickness of the bowel wall rather than affecting only the inner lining. |
| Skip lesions | Patches of inflamed bowel separated by stretches of completely normal tissue, a pattern typical of Crohn’s disease. |
| Stricture | A segment of intestine narrowed by long-standing inflammation and scarring, which can slow or block the passage of food. |
| Fistula | An abnormal tunnel that forms between the bowel and another organ or the skin, most often near the anus in Crohn’s disease. |
| Endoscopic healing | The closure of visible ulcers seen during a colonoscopy. It is a stricter treatment target than symptom relief alone. |
| Therapeutic drug monitoring | Blood testing that measures how much of a medication is circulating and whether the immune system has produced antibodies against it. |
Frequently asked questions
Is Crohn’s disease curable?
No treatment currently cures Crohn’s disease, and surgery does not cure it either, because inflammation can return at the site where the bowel was rejoined. What has changed is what remission can look like. With current therapies, many people reach a state where ulcers have healed, markers are normal and symptoms are absent for years at a time. The practical goal your team will discuss is long-term control with the lowest medication burden that keeps the bowel healed, along with regular monitoring so that a returning flare is caught early rather than after damage has occurred.
Can a blood test diagnose Crohn’s disease?
Not on its own. Blood tests support the diagnosis and are essential for monitoring, but no single blood result confirms or excludes Crohn’s. A raised C-reactive protein, a low hemoglobin, a low albumin or low iron stores all raise suspicion and justify further testing. Stool calprotectin is more specific to intestinal inflammation than any blood marker, which is why it is usually ordered alongside blood work. Confirmation still requires ileocolonoscopy with biopsies, supported by imaging of the small intestine when needed.
What does undiagnosed Crohn’s disease feel like?
Most people describe months or years of symptoms that seemed explainable: recurrent cramping after meals, loose stools that come and go, fatigue attributed to a busy life, occasional mouth ulcers, and slow weight loss. Night-time diarrhea, blood in the stool, fever without an infection and weight loss you did not intend are the features that most often prompt a proper workup. If that combination sounds familiar, a stool calprotectin test and basic blood work are a reasonable first step to discuss with a doctor.
Do Crohn’s disease symptoms differ in women and men?
The core digestive symptoms are the same. Some differences relate to reproductive health rather than the bowel itself: symptoms can shift around the menstrual cycle, iron deficiency is more common in menstruating women, and pregnancy planning benefits from entering conception in remission. Men more often report perianal disease in some series. Both sexes can experience joint, skin and eye involvement. The monitoring approach, including stool and blood markers, is the same regardless of sex.
Is Crohn’s disease hereditary?
There is a genetic component, but Crohn’s is not inherited in a straightforward way. Mayo Clinic reports that up to one in five people with the disease has a close relative with inflammatory bowel disease, which also means most patients have no affected relative. Dozens of gene variants have been linked to risk, each contributing a small amount, and they only translate into disease when environmental factors are also present. Having a parent with Crohn’s raises your risk above average but does not make the diagnosis likely.
How often should lab markers be rechecked?
There is no universal schedule, and your gastroenterologist sets the interval based on how stable you are. In practice, markers are commonly checked more frequently in the months after starting or changing a treatment, and less often once remission is established and stable. Testing is also repeated whenever symptoms change, before a treatment decision, and after intestinal surgery to detect early recurrence. What matters more than the exact frequency is consistency, so the trend over time can be read rather than isolated values.
Sources
- National Institute of Diabetes and Digestive and Kidney Diseases — Crohn’s Disease, 2024 — niddk.nih.gov
- Mayo Clinic — Crohn’s disease: Symptoms and causes, 2026 — mayoclinic.org
- Cleveland Clinic — Crohn’s Disease: Symptoms and Treatment, 2026 — my.clevelandclinic.org
- Ananthakrishnan AN, Adler J, Chachu KA, et al. — AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn’s Disease — Gastroenterology, 2023 — doi.org/10.1053/j.gastro.2023.09.029
- Dolinger M, Torres J, Vermeire S — Crohn’s disease — The Lancet, 2024 — doi.org/10.1016/S0140-6736(23)02586-2
- Noor NM, Lee JC, Bond S, et al. — A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE) — The Lancet Gastroenterology and Hepatology, 2024 — doi.org/10.1016/S2468-1253(24)00034-7
- Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. — Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease — New England Journal of Medicine, 2024 — doi.org/10.1056/NEJMoa2314585
- Magro F, Estevinho MM, Catalano G, et al. — Longitudinal profiles of fecal calprotectin and C-reactive protein in relation to outcomes in Crohn’s disease patients on infliximab — Journal of Crohn’s and Colitis, 2025 — doi.org/10.1093/ecco-jcc/jjaf120
- Roblin X, Nancey S, Papamichael K, et al. — Therapeutic drug monitoring in inflammatory bowel disease: recent developments — Expert Review of Gastroenterology and Hepatology, 2024 — doi.org/10.1080/17474124.2024.2409300
- Felipez LM, Kim MO, Colletti RB, et al. — NASPGHAN position paper on therapeutic drug monitoring in pediatric inflammatory bowel disease — Journal of Pediatric Gastroenterology and Nutrition, 2025 — doi.org/10.1002/jpn3.70158
- Hirten RP, Danieletto M, Landell K, et al. — Physiological Data Collected From Wearable Devices Identify and Predict Inflammatory Bowel Disease Flares — Gastroenterology, 2025 — doi.org/10.1053/j.gastro.2024.12.024
- Auerbach M, DeLoughery TG, Tirnauer JS — Iron Deficiency in Adults: A Review — JAMA, 2025 — doi.org/10.1001/jama.2025.0452
Further reading
- Fecal lactoferrin test results
- Total iron-binding capacity explained
- Clostridioides difficile toxin levels
- Stool test interpretation
- Gut, blood and metabolism markers read together
Understand your lab results with BloodSense
Crohn’s disease is followed as much through laboratory numbers as through symptoms, and those numbers are easy to misread on your own. BloodSense reads your stool and blood reports and explains, in plain language, what a fecal calprotectin result, a C-reactive protein value, a complete blood count, ferritin or vitamin B12 actually indicate and how they relate to each other. It helps you arrive at your appointment understanding your own results and knowing what to ask. BloodSense does not diagnose and does not replace your gastroenterologist.
